Login to Your Account

Triangle Files First NDA, Seeks Approval Of Coviracil For HIV

By Kim Coghill

Friday, September 6, 2002
In early August, Triangle Pharmaceuticals Inc.'s stock shot up surrounding favorable interim data from a Phase III trial of the company's lead product candidate for HIV. And Thursday, the stock was up again when Triangle said it had taken the positive data and filed its first new drug application. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription